Sign In

Christopher Rudd

Professeur, Université de Montreal

Christopher E. Rudd is a distinguished immunologist and researcher with a focus on T-cell signaling and cancer immunotherapy. He currently holds several academic positions:

Academic Appointments

  • Full-time Professor (accredited) at Université de Montréal in the Department of Microbiology, Infection and Immunology13
  • Adjunct Professor in the Department of Medicine at McGill University24
  • Full member of the McGill Centre for Translational Research in Cancer12

Research Focus

Dr. Rudd's research primarily concentrates on:

  • Receptors and signaling pathways of T-cells in the immune system
  • Control of T-cell reactivity and tumor rejection
  • Identification of key mediators in T-cell function for cancer treatment

His lab has made significant contributions to the field, including:

  • Discovery of CD4 and CD8-p56lck complexes and adaptor proteins
  • Identification of pathways for CD28, CTLA-4, and ICOS co-receptor function
  • Laying the foundation for chimeric antigen receptor (CAR) cancer therapy
  • Identifying glycogen synthase kinase (GSK-3) as a central regulator of PD-1 expression on T cells1

Education and Career

Dr. Rudd received his BSc from McGill University in Canada and his Ph.D. and D.Sc. degrees from University College London in the UK.7 He has had a distinguished career in immunology research, holding various positions before his current roles at Université de Montréal and McGill University.

Honors and Affiliations

Christopher E. Rudd holds several prestigious titles:

  • FRCPath (Fellow of the Royal College of Pathologists)
  • FMedSci (Fellow of the Academy of Medical Sciences)
  • FRSC (Fellow of the Royal Society of Canada)5

His LinkedIn profile, under the username chrudd, indicates that he is based in Montréal-Ouest and has over 500 connections in his professional network.6

Highlights

Jun 11 · linkedin

Our humble contribution to the COVID-19 field. A super collaboration involving colleagues Drs. Richard Kremer and Catalin Mihalcioiu at McGill University Health Centre (MUHC) and the CR-HMR. Late but it makes a novel contribution by showing that within the MUHC patient population infected with SARs CoV-2, the severity of disease was linked to the preferential loss of TCF1+ stem-like progenitor T-cells needed to replenish the peripheral immune response. In our model, the cytokine storm leads to the preferential loss of progenitor CD4 and CD8 T-cells marked by either the loss of TCF1+ cells or their capacity to divide and expand. Few progenitors in the immune system= no protective immunity.

Nov 24 · linkedin

It’s been a while since I’ve completed my program at University of Cambridge, but I wanted to share this update with everyone.

Related Questions

What are some of Christopher Rudd's most significant contributions to cancer research?
How does Christopher Rudd's work on CD28 and CTLA-4 co-receptors impact immunotherapy?
What role does glycogen synthase kinase (GSK-3) play in Christopher Rudd's research?
Can you explain the significance of the CD4 and CD8-p56 lck complexes discovered by Rudd's lab?
What are the potential applications of small molecule inhibitors (SMIs) identified by Rudd's lab?
Christopher Rudd
Christopher Rudd, photo 1
Christopher Rudd, photo 2
Add to my network

Location

Montréal-Ouest, Quebec, Canada